AZ’s Enhertu data highlight value of continued HER2 innovation 

It’s no surprise that AstraZeneca’s Enhertu outperformed Kadcyla in a head-to-head second-line breast cancer trial, but the magnitude of the progression-free survival advantage went well beyond expectations and represents the kind of meaningful advance that industry is striving for with next-generation modalities.

It also showcases the untapped value still present in the established target HER2, which is in the crosshairs of many next-generation antibody developers...